ID   CDKN3_HUMAN             Reviewed;         212 AA.
AC   Q16667; Q53ZU6; Q5U0M4; Q6P1N8; Q99585; Q9BPW7; Q9BY36; Q9C042;
AC   Q9C046; Q9C047; Q9C049; Q9C051; Q9C053;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 3;
DE            EC=3.1.3.16;
DE            EC=3.1.3.48;
DE   AltName: Full=CDK2-associated dual-specificity phosphatase;
DE   AltName: Full=Cyclin-dependent kinase interactor 1;
DE   AltName: Full=Cyclin-dependent kinase-interacting protein 2;
DE   AltName: Full=Kinase-associated phosphatase;
GN   Name=CDKN3; Synonyms=CDI1, CIP2, KAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   CDK1; CDK2 AND CDK3.
RX   PubMed=8242750; DOI=10.1016/0092-8674(93)90498-F;
RA   Gyuris J., Golemis E., Chertkov H., Brent R.;
RT   "Cdi1, a human G1 and S phase protein phosphatase that associates with
RT   Cdk2.";
RL   Cell 75:791-803(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   CDK1 AND CDK2.
RX   PubMed=8127873; DOI=10.1073/pnas.91.5.1731;
RA   Hannon G.J., Casso D., Beach D.;
RT   "KAP: a dual specificity phosphatase that interacts with cyclin-
RT   dependent kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1731-1735(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS HCC
RP   ARG-31; LEU-78; TYR-79; LYS-91; VAL-94; PHE-95; VAL-108; SER-187 AND
RP   ILE-195.
RX   PubMed=10987270;
RA   Yeh C.-T., Lu S.-C., Chen T.-C., Peng C.-Y., Liaw Y.-F.;
RT   "Aberrant transcripts of the cyclin-dependent kinase-associated
RT   protein phosphatase in hepatocellular carcinoma.";
RL   Cancer Res. 60:4697-4700(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH CDK2.
RX   PubMed=12745075; DOI=10.1016/S0006-291X(03)00757-5;
RA   Yeh C.-T., Lu S.-C., Chao C.-H., Chao M.-L.;
RT   "Abolishment of the interaction between cyclin-dependent kinase 2 and
RT   Cdk-associated protein phosphatase by a truncated KAP mutant.";
RL   Biochem. Biophys. Res. Commun. 305:311-314(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Harper W., Elledge S.J.;
RL   Submitted (NOV-1993) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Schupp I.;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Retinoblastoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=7569954; DOI=10.1126/science.270.5233.90;
RA   Poon R.Y.C., Hunter T.;
RT   "Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-
RT   interacting phosphatase KAP in the absence of cyclin.";
RL   Science 270:90-93(1995).
RN   [13]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=10669749; DOI=10.1128/MCB.20.5.1723-1732.2000;
RA   Lee S.W., Reimer C.L., Fang L., Iruela-Arispe M.L., Aaronson S.A.;
RT   "Overexpression of kinase-associated phosphatase (KAP) in breast and
RT   prostate cancer and inhibition of the transformed phenotype by
RT   antisense KAP expression.";
RL   Mol. Cell. Biol. 20:1723-1732(2000).
RN   [14]
RP   INTERACTION WITH MS4A3.
RX   PubMed=11781350; DOI=10.1172/JCI0214025;
RA   Donato J.-L., Ko J., Kutok J.L., Cheng T., Shirakawa T., Mao X.-Q.,
RA   Beach D., Scadden D.T., Sayegh M.H., Adra C.N.;
RT   "Human HTm4 is a hematopoietic cell cycle regulator.";
RL   J. Clin. Invest. 109:51-58(2002).
RN   [15]
RP   INTERACTION WITH MS4A3.
RX   PubMed=15671017; DOI=10.1074/jbc.M413437200;
RA   Chinami M., Yano Y., Yang X., Salahuddin S., Moriyama K.,
RA   Shiroishi M., Turner H., Shirakawa T., Adra C.N.;
RT   "Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated
RT   phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase
RT   activity of KAP, dissociates cyclin A, and facilitates KAP
RT   dephosphorylation of Cdk2.";
RL   J. Biol. Chem. 280:17235-17242(2005).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH THR-160
RP   PHOSPHORYLATED CDK2.
RX   PubMed=11463386; DOI=10.1016/S1097-2765(01)00208-8;
RA   Song H., Hanlon N., Brown N.R., Noble M.E.M., Johnson L.N.,
RA   Barford D.;
RT   "Phosphoprotein-protein interactions revealed by the crystal structure
RT   of kinase-associated phosphatase in complex with phosphoCDK2.";
RL   Mol. Cell 7:615-626(2001).
CC   -!- FUNCTION: May play a role in cell cycle regulation. Dual
CC       specificity phosphatase active toward substrates containing either
CC       phosphotyrosine or phosphoserine residues. Dephosphorylates CDK2
CC       at 'Thr-160' in a cyclin-dependent manner.
CC       {ECO:0000269|PubMed:7569954, ECO:0000269|PubMed:8127873,
CC       ECO:0000269|PubMed:8242750}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC   -!- SUBUNIT: Interacts with cyclin-dependent kinases such as CDK1,
CC       CDK2 and CDK3. Does not interact with CDK4. Interacts (via C-
CC       terminus) with phosphorylated CDK2 (via C-terminal helix).
CC       Interacts with MS4A3 (via C-terminus); the interaction enhances
CC       CDKN3 enzymatic activity. {ECO:0000269|PubMed:11463386,
CC       ECO:0000269|PubMed:11781350, ECO:0000269|PubMed:12745075,
CC       ECO:0000269|PubMed:15671017, ECO:0000269|PubMed:8127873,
CC       ECO:0000269|PubMed:8242750}.
CC   -!- INTERACTION:
CC       P24941:CDK2; NbExp=6; IntAct=EBI-1031527, EBI-375096;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:10669749}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16667-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16667-2; Sequence=VSP_036613;
CC   -!- INDUCTION: Up-regulated in breast and prostate cancer cells.
CC       {ECO:0000269|PubMed:10669749}.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk
CC       factors for HCC are chronic hepatitis B virus (HBV) infection,
CC       chronic hepatitis C virus (HCV) infection, prolonged dietary
CC       aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to
CC       other causes. {ECO:0000269|PubMed:10987270}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdkn3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U02681; AAC04932.1; -; mRNA.
DR   EMBL; L27711; AAA66496.1; -; mRNA.
DR   EMBL; AF213033; AAK06365.1; -; mRNA.
DR   EMBL; AF213036; AAK06368.1; -; mRNA.
DR   EMBL; AF213038; AAK06370.1; -; mRNA.
DR   EMBL; AF213039; AAK06371.1; -; mRNA.
DR   EMBL; AF213041; AAK06373.1; -; mRNA.
DR   EMBL; AF213042; AAK06374.1; -; mRNA.
DR   EMBL; AF213046; AAK06377.1; -; mRNA.
DR   EMBL; AF213047; AAK06378.1; -; mRNA.
DR   EMBL; AF213049; AAK06380.1; -; mRNA.
DR   EMBL; AF213053; AAK06384.1; -; mRNA.
DR   EMBL; AY257474; AAP13062.1; -; mRNA.
DR   EMBL; L25876; AAA60222.1; -; mRNA.
DR   EMBL; EF560750; ABQ59060.1; -; mRNA.
DR   EMBL; CR407666; CAG28594.1; -; mRNA.
DR   EMBL; BT019451; AAV38258.1; -; mRNA.
DR   EMBL; AY194117; AAN86348.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW80632.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW80634.1; -; Genomic_DNA.
DR   EMBL; BC064965; AAH64965.1; -; mRNA.
DR   CCDS; CCDS45109.1; -. [Q16667-2]
DR   CCDS; CCDS9716.1; -. [Q16667-1]
DR   PIR; A49436; A49436.
DR   RefSeq; NP_001124323.1; NM_001130851.1. [Q16667-2]
DR   RefSeq; NP_005183.2; NM_005192.3. [Q16667-1]
DR   UniGene; Hs.84113; -.
DR   PDB; 1FPZ; X-ray; 2.00 A; A/B/C/D/E/F=1-212.
DR   PDB; 1FQ1; X-ray; 3.00 A; A=1-212.
DR   PDBsum; 1FPZ; -.
DR   PDBsum; 1FQ1; -.
DR   ProteinModelPortal; Q16667; -.
DR   SMR; Q16667; -.
DR   BioGrid; 107467; 5.
DR   DIP; DIP-24231N; -.
DR   DIP; DIP-245N; -.
DR   IntAct; Q16667; 4.
DR   MINT; MINT-204916; -.
DR   STRING; 9606.ENSP00000335357; -.
DR   DEPOD; Q16667; -.
DR   iPTMnet; Q16667; -.
DR   PhosphoSitePlus; Q16667; -.
DR   BioMuta; CDKN3; -.
DR   DMDM; 2499769; -.
DR   EPD; Q16667; -.
DR   MaxQB; Q16667; -.
DR   PaxDb; Q16667; -.
DR   PeptideAtlas; Q16667; -.
DR   PRIDE; Q16667; -.
DR   DNASU; 1033; -.
DR   Ensembl; ENST00000335183; ENSP00000335357; ENSG00000100526. [Q16667-1]
DR   Ensembl; ENST00000442975; ENSP00000415333; ENSG00000100526. [Q16667-2]
DR   GeneID; 1033; -.
DR   KEGG; hsa:1033; -.
DR   UCSC; uc001xap.4; human. [Q16667-1]
DR   CTD; 1033; -.
DR   DisGeNET; 1033; -.
DR   GeneCards; CDKN3; -.
DR   HGNC; HGNC:1791; CDKN3.
DR   HPA; CAB005285; -.
DR   HPA; HPA039311; -.
DR   HPA; HPA058874; -.
DR   MalaCards; CDKN3; -.
DR   MIM; 114550; phenotype.
DR   MIM; 123832; gene.
DR   neXtProt; NX_Q16667; -.
DR   OpenTargets; ENSG00000100526; -.
DR   PharmGKB; PA26324; -.
DR   eggNOG; KOG1720; Eukaryota.
DR   eggNOG; COG2453; LUCA.
DR   GeneTree; ENSGT00390000004717; -.
DR   HOVERGEN; HBG075798; -.
DR   InParanoid; Q16667; -.
DR   KO; K14167; -.
DR   OMA; TVKQYNF; -.
DR   OrthoDB; EOG091G0MIF; -.
DR   PhylomeDB; Q16667; -.
DR   TreeFam; TF101040; -.
DR   SIGNOR; Q16667; -.
DR   ChiTaRS; CDKN3; human.
DR   EvolutionaryTrace; Q16667; -.
DR   GeneWiki; CDKN3; -.
DR   GenomeRNAi; 1033; -.
DR   PRO; PR:Q16667; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100526; -.
DR   ExpressionAtlas; Q16667; baseline and differential.
DR   Genevisible; Q16667; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:MGI.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:MGI.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; TAS:ProtInc.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:MGI.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR008425; CDK_inhib_3.
DR   InterPro; IPR022778; CDKN3.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF05706; CDKN3; 1.
DR   PIRSF; PIRSF037322; CDKN3; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Complete proteome;
KW   Cytoplasm; Disease mutation; Hydrolase; Polymorphism;
KW   Protein phosphatase; Reference proteome.
FT   CHAIN         1    212       Cyclin-dependent kinase inhibitor 3.
FT                                /FTId=PRO_0000094949.
FT   REGION        1     34       Interaction with CDK2.
FT   ACT_SITE    140    140       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   VAR_SEQ      11     50       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10987270,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036613.
FT   VARIANT      31     31       W -> R (in HCC; patient BX-01).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013842.
FT   VARIANT      78     78       F -> L (in HCC; patient T9).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013843.
FT   VARIANT      79     79       C -> Y (in HCC; patient BX-01).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013844.
FT   VARIANT      91     91       N -> K (in HCC; patient BX-10;
FT                                dbSNP:rs760687800).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013845.
FT   VARIANT      94     94       D -> V (in HCC; patient NT1).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013846.
FT   VARIANT      95     95       L -> F (in HCC; patient BX-05).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013847.
FT   VARIANT     108    108       I -> V (in HCC; patient T9;
FT                                dbSNP:rs144479038).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013848.
FT   VARIANT     159    159       S -> F (in dbSNP:rs1803843).
FT                                /FTId=VAR_051769.
FT   VARIANT     187    187       N -> S (in HCC; patient NT4).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013849.
FT   VARIANT     195    195       K -> I (in HCC; patient NT4).
FT                                {ECO:0000269|PubMed:10987270}.
FT                                /FTId=VAR_013850.
FT   CONFLICT      2      2       K -> E (in Ref. 1; AAC04932 and 8;
FT                                AAV38258). {ECO:0000305}.
FT   CONFLICT     10     10       S -> G (in Ref. 3; AAK06380).
FT                                {ECO:0000305}.
FT   STRAND       30     33       {ECO:0000244|PDB:1FPZ}.
FT   HELIX        35     37       {ECO:0000244|PDB:1FPZ}.
FT   STRAND       42     47       {ECO:0000244|PDB:1FPZ}.
FT   HELIX        60     70       {ECO:0000244|PDB:1FPZ}.
FT   STRAND       74     77       {ECO:0000244|PDB:1FPZ}.
FT   HELIX        81     86       {ECO:0000244|PDB:1FPZ}.
FT   HELIX        92     98       {ECO:0000244|PDB:1FPZ}.
FT   STRAND      102    105       {ECO:0000244|PDB:1FPZ}.
FT   HELIX       116    131       {ECO:0000244|PDB:1FPZ}.
FT   STRAND      136    139       {ECO:0000244|PDB:1FPZ}.
FT   STRAND      141    145       {ECO:0000244|PDB:1FPZ}.
FT   HELIX       146    158       {ECO:0000244|PDB:1FPZ}.
FT   STRAND      160    162       {ECO:0000244|PDB:1FQ1}.
FT   HELIX       164    175       {ECO:0000244|PDB:1FPZ}.
FT   HELIX       183    189       {ECO:0000244|PDB:1FPZ}.
FT   HELIX       192    197       {ECO:0000244|PDB:1FPZ}.
FT   TURN        198    200       {ECO:0000244|PDB:1FQ1}.
SQ   SEQUENCE   212 AA;  23805 MW;  D87FAC8E28F6525F CRC64;
     MKPPSSIQTS EFDSSDEEPI EDEQTPIHIS WLSLSRVNCS QFLGLCALPG CKFKDVRRNV
     QKDTEELKSC GIQDIFVFCT RGELSKYRVP NLLDLYQQCG IITHHHPIAD GGTPDIASCC
     EIMEELTTCL KNYRKTLIHC YGGLGRSCLV AACLLLYLSD TISPEQAIDS LRDLRGSGAI
     QTIKQYNYLH EFRDKLAAHL SSRDSQSRSV SR
//
